Patients w/ well-compensated heart failure, myasthenia gravis, DM, 1st degree AV block. May mask symptoms of hyperthyroidism and hypoglycaemia. May worsen psoriasis. Patients undergoing major surgery requiring general anaesth. Avoid abrupt withdrawal as it may precipitate thyroid storm and exacerbate angina and MI. Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor BP, heart rate, serum creatinine; Mg and K levels.
Bronchial asthma or history of COPD, sick sinus syndrome, symptomatic sinus bradycardia, cardiogenic shock. 2nd and 3rd degree AV block, untreated phaeochromocytoma, torsades de pointes, congenital or acquired long QT syndromes, uncontrolled cardiac failure, cardiogenic shock, metabolic acidosis, hypotension, severe peripheral arterial disease, Raynaud's disease, anaesthesia that causes myocardial depression. Renal impairment (CrCl <10 mL/min). Concomitant use w/ Ca channel blockers (e.g. verapamil and diltiazem).
Dose
N/A
Side Effect
>10%
Dyspnea (21%),Dizziness (20%),Fatigue (20%),Bradycardia (16%),Chest pain (16%),Palpitation (14%),Weakness (13%),Lightheadedness (12%)
1-10%
Nausea/vomiting (10%),Edema (8%),Headache (8%),Sleep disturbances (8%),Abnormal ECG (7%),Diarrhea (7%),Extremity pain (7%),Hypotension (6%),Mental confusion (6%),Congestive heart failure (5%),Itching/rash (5%),Syncope (5%),Anxiety (4%),Depression (4%),Torsades de pointes or new ventricular tachycardia/fibrillation in patients with supraventricular arrhythmia (4%),Peripheral vascular disorders (3%),Impotence (2%),Proarrhythmic effect (1.5-2%),Torsades de pointes with history of sustained ventricular tachycardia (1%)
Frequency Not Defined
Catechol hypersensitivity after abrupt withdrawal,Increased insulin requirement in diabetics
Potentially Fatal: Polymorphic ventricular tachycardia (very rare). Rebound hypertension.
Pregnancy Category
Name :
D
Description
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Mode of Action
Sotalol is a non-cardioselective beta-blocker. It increases sinus cycle length, slows heart rate, decreases AV nodal conduction and increases AV nodal refractoriness. It also prolongs AV monophasic action potentials. However, it lacks intrinsic sympathomimetic and membrane-stabilising properties.
Interaction
May increase risk of bradycardia w/ digoxin. May increase risk of arrhythmias w/ diuretics. May potentiate rebound HTN w/ clonidine. May prolong refractoriness w/ disopyramide, quinidine, procainamide, amiodarone and bepridil. May prolong QT interval w/ TCAs, phenothiazines, terfenadine and astemizole. Increased risk of torsades de pointes w/ K-depleting diuretics, erythromycin IV, halofantrine, pentamidine, and quinolones. May prolong neuromuscular blockade of tubocurarine. May reduce response to insulin and oral hypoglycaemics.
Potentially Fatal: Additive effect on AV conduction and ventricular function w/ verapamil and diltiazem.
Pregnancy Category Note
Pregnancy category: B
Lactation: Drug present in breast milk; do not nurse while taking
Adult Dose
Oral
Supraventricular and ventricular arrhythmias
Adult: Initially, 80 mg/day as single or in 2 divided doses, increased gradually every 2-3 days. Usual dose: 160-320 mg/day in 2 divided doses.
Life-threatening ventricular arrhythmias
Adult: Initially, 80 mg bid, increased gradually every 3 days to 240-320 mg/day in divided doses if needed. Maintenance: 160-320 mg/day in divided doses. Max: 480-640 mg in divided doses.
Child Dose
N/A
Renal Dose
Renal impairment:
CrCl (ml/min) Dosage Recommendation
30-60 Half the usual dose.
10-30 Quarter the usual dose.
<10 Not recommended.
Administration
Should be taken on an empty stomach. Take 1-2 hr before meals.
Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.